Protokoly_diagnostiki_i_lechenia_zabolevany

" & :

1.*/ 250 , 500

2.* V 40 / , 80 /2

3.*B 25

4.*@ ( ) 0,1% 10

" & :

,- ! ( ! ):

1." # - " , ,.

2.3 / 3 " " 5 .

/ , & :

1.EBM Guidelines. Iridocyclitis. 2004

2.Dunne JA. Travers JP. Topical steroids in anterior uvetis. Trans Ophthalmol Soc UK 1979, 99: 481-484.

3.Foster CS, Alter G, Debarge RL, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996; 122: 171-182.

4.The Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of Loterpredol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999; 127: 537-544.

5.Yang BJ, Cunningham WF, Akingbehin T. Double-masked controlled clinical trial of 5% tolmetin versus 0,5% prednisolone versus 0,9% saline in acute endogenous nongranulomatous anterior uveitis. Br J Ophthalmol 1982, 66: 389391.

* – , # (% % ) .

" . ? & .

6 , , 3 . B , ,& " , .

" & :

1.&

2.& 3

3.& &

5.&

6.;

7.<

9.$

" & & :

1._ $

2.H)B

3.$ " ( " )

4./

5.&$ ( " )

+ :

" 3 & $# & : ", " & , ,

" , & , & .

" & :

1.6 V 500 ,

2.*7 250

3.*? 50 , 100 , 500 ; V 5%, 10%2 , 5

4., % #

5.*' 5 , 10 ; V 2

6.*@ "& V 40 /10%, 20%

" & & :

,- !: &

/ , & :

1.American Academy of Ophthalmology. Guideline. Diabetic Retinopathy. 2003.

2.EBM Guidelines. Diabetic eye disease, with special reference to diabetic retinopathy. 2004. 3.American Academy of Ophthalmology. Diabetic Retinopathy (Initial and Follow-up Evaluation). 2003.

4.ICO International Clinical Guidelines. . Diabetic Retinopathy (Initial and Follow-up Evaluation). 2005.

5.@ & . >% " . 2003 – L & 7. – !. 2360-2370.

* – , # (% % ) .

9

: 03-029

"$ &: "

: 6!

& ! : , .(: J01

J01.0 "$

J01.9 "

J32 G "

J32.0 G " "$

J32.4 G "

J32.8 @ "

J32.9 G " "

) : ' " " , " % & , , & " .

$ :

1.( & , )

2." ( , , " , -) * : ? . L .

: @ &V , ,% .

@ & % &

+ : ? & . @ $" " &" & [ & "'@ " % " %

& (?). @ 2 % "& , " % , " 45 / / & [ 90 / / & [ . >% " : (14 / / & 1-2

" - 80-90 / / &6,4 / / & [ . ? &" , , .

(50 / / &) " & "

& & " 5 \ \ & " 5 .

' & & .: " & % # ( " " ),; , $# $ %$# ( & ), " , .

" & :

1.*? 250 ; 250 , 500 ; V 500 , 1000 ; 125/5

2.*/ 250 , 500 ; V750

3.250 , 500

4.V 300 /2 ,

5.*? + 625 ; V 600

6. / V

7.*/ V 250 , 500 , 1 000

8.*B & 150 – 10 \

" & & :

,- ! :

3 " " , % .

/ , & :

1.' # " . " . @ ;.?..

2.The diagnosis and management of acute bacterial sinusitis. Guideline. Alberta Medical Association. November 2001.

3.Acute sinusitis: A cost-effective approach to diagnosis and treatment. Guideline. American Family Physician. November 1998.

4.Sinusitis in children. EBM Guidelines. 2004.

5.AAP Issues Recommendations for the Management of Sinusitis in Children. Practice Guidelines. American Family Physician. 2002.

6.Clinical Practice Guideline: Management of Sinusitis. American Academy of Pediatrics. 2001.

7.Acute Bacterial Sinusitis in Children 1 to 18 years of age. Evidence Based Clinical Practice Guideline. Children s Hospital Medical Center Cincinnati. 2001.

8.Prodigy Guidance-Sinusitis. 2004.

* – , # (% % ) .

9

: 03-029

"$ &: "

: 6!

& ! : ' , .

) : ' " " , " % & , , &

V , ,% .

@ & % &

+ : ? & . @ $" " &" & [ & "'@ " % " %

& (?).250-500 3 &. > % & ," – $ " & " + 250/1000 2-3 &. ? &" , . (50 / / &) " & " , $# " & & . L 24 " " " , & [ . >" , / % " , # 2 . & & &$ , " " & &

" & :

1.*? 250 ; 250 , 500 ; V 500 , 1000 ; 125/5

2.*/ 250 , 500 ; V750

3.250 , 500

4.V 300 /2 ,

5.*? + 625 ; V 600

6. / V

7.*/ V 250 , 500 , 1 000

8.*B & 150 – 10 \

" & & :

,- ! : 3 " " ,% .

/ , & :

1.' # " . " . @ ;.?..

2.The diagnosis and management of acute bacterial sinusitis. Guideline. Alberta Medical Association. November 2001.

3.Acute sinusitis: A cost-effective approach to diagnosis and treatment. Guideline. American Family Physician. November 1998.

4.Health Care Guideline: Acute sinusitis in adults. Institute for Clinical System Improvement. 2004.

5.Prodigy Guidance-Sinusitis. 2004

* – , # (% % ) .

) : + 8 - & % " , %. 6 % % & " % " . $ & & .

; " "$ ,$# $& % . 7 % - ,$# & " , % " " .

$ :

: , * : 40 , " ,

, % " – ( ", $ & ), % ,

3.& &

4.; &

5.J

" & :

1.#

2.!-

3.1 ( , , , " , " & , )

4.; 3

6._

7.H &

8.@

10.&

" & & :

1. # "

+

# : , , " ,3 " .

:

@ & & & % & " & % "( , V % , – , $# " & " % " $ ).

% (3 " , & , )& , 3 3 % && .

% " 3–5 % & $, & " " 30% #. ; & $ ,

$ $ # & $# . + " " 10 V ,& (4).

& – 400 3 &,1 3 &, 250 2 &, 50 2 &, 1 4 &.

6

" & :

1.* V

2.@ V 100 6>

3.+ V 2850 6>, 3800 6>, 5700 6>, 7600 6>

4.*B 200 , 400

5.*? 300-500

6.+ 250

7.*@ 25 , 100 , 150

8.* 200 , 500

" & & :

$. + 3 & " ;, $.

/ , & :

1.Brandjes DPM, Heijboer H, Buller HR, Rijk M, Jagt H, Ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485-1489;

2.Lagerstedt C, Olsson C, Fagher B, Oqvist B, Albrechtsson U. Need for long term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985; 334: 515-518;

3.Barrit DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; i:1309-1312;

4. '.?., ; : " , 2003;

5.Prodigy Guidance – Thromophlebitis, 2005;

* – , # (% % ) .